Wall Street Zen Upgrades Aldeyra Therapeutics (NASDAQ:ALDX) to "Hold"

Aldeyra Therapeutics (NASDAQ:ALDX - Get Free Report) was upgraded by equities research analysts at Wall Street Zen from a "sell" rating to a "hold" rating in a research report issued on Saturday.

A number of other analysts have also recently commented on the stock. HC Wainwright reiterated a "buy" rating and issued a $10.00 price target on shares of Aldeyra Therapeutics in a research note on Monday, May 19th. BTIG Research lowered their price target on shares of Aldeyra Therapeutics from $11.00 to $9.00 and set a "buy" rating on the stock in a research report on Monday, April 7th.

Aldeyra Therapeutics Trading Down 3.8%

Shares of ALDX stock traded down $0.12 on Friday, reaching $3.05. 801,493 shares of the stock were exchanged, compared to its average volume of 826,542. The stock has a market cap of $182.70 million, a PE ratio of -3.14 and a beta of 0.68. Aldeyra Therapeutics has a one year low of $1.14 and a one year high of $7.20. The company has a debt-to-equity ratio of 0.24, a current ratio of 6.49 and a quick ratio of 6.49. The stock has a 50 day moving average price of $2.45 and a 200 day moving average price of $4.32.

Aldeyra Therapeutics (NASDAQ:ALDX - Get Free Report) last issued its quarterly earnings data on Wednesday, May 14th. The biotechnology company reported ($0.17) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.25) by $0.08. Equities research analysts forecast that Aldeyra Therapeutics will post -0.92 EPS for the current fiscal year.

Insider Activity

In other news, major shareholder Perceptive Advisors Llc sold 3,400,000 shares of the business's stock in a transaction on Thursday, April 3rd. The stock was sold at an average price of $1.42, for a total transaction of $4,828,000.00. Following the completion of the transaction, the insider now owns 5,875,851 shares of the company's stock, valued at approximately $8,343,708.42. The trade was a 36.65% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 9.60% of the company's stock.

Institutional Trading of Aldeyra Therapeutics

Several large investors have recently bought and sold shares of the business. Geode Capital Management LLC lifted its holdings in shares of Aldeyra Therapeutics by 0.4% in the fourth quarter. Geode Capital Management LLC now owns 1,119,555 shares of the biotechnology company's stock worth $5,588,000 after acquiring an additional 4,927 shares during the last quarter. Wells Fargo & Company MN grew its position in Aldeyra Therapeutics by 1.9% during the 4th quarter. Wells Fargo & Company MN now owns 393,654 shares of the biotechnology company's stock worth $1,964,000 after acquiring an additional 7,348 shares during the last quarter. Intech Investment Management LLC increased its holdings in Aldeyra Therapeutics by 62.7% in the 4th quarter. Intech Investment Management LLC now owns 23,806 shares of the biotechnology company's stock worth $119,000 after purchasing an additional 9,178 shares in the last quarter. Barclays PLC raised its position in Aldeyra Therapeutics by 14.9% in the fourth quarter. Barclays PLC now owns 75,330 shares of the biotechnology company's stock valued at $376,000 after purchasing an additional 9,769 shares during the last quarter. Finally, Hsbc Holdings PLC acquired a new stake in shares of Aldeyra Therapeutics during the fourth quarter valued at about $52,000. 59.71% of the stock is owned by institutional investors and hedge funds.

About Aldeyra Therapeutics

Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company's lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A.